Akihiko Matsuda, Tateki Kitaoka and Hiromichi Suzuki
Background: The introduction of erythropoietinn stimulating agent (ESA) in clinical practice has completely altered the management of patients with chronic kidney disease. However, the successful correction of anemia has not always resulted in improvement of mortality in CKD patients. One of the main reasons for failure of preservation of renal function is excessive elevation of hemoglobin (Hb) levels for CKD patients. This indicates the need for maintaining appropriate target levels of Hb to preclude the progression of CKD. The aim of this study was to compare the effects of two Hb levels on progression of CKD patients in a 2 year period. Subjects: A total of 167 patients with chronic kidney disease (2mg
Compartilhe este artigo
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi 